How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization? December 7, 2022 Issue Brief This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.
The Secret to a Safe Reopening June 26, 2020 Blog As countries around the world begin to reopen, those that waited for the right time to ease lockdown restrictions seem to be in better shape than those who reopened despite higher levels of coronavrius transmission and lower public health capacity. In an article for Foreign Affairs, KFF’s Jen Kates and…
